Avrobio takes a second stab at a good first impression — but durability questions still dog gene therapy
Four months ago, Avrobio’s shares $AVRO were subjected to a ritual slaughter on Wall Street after investors were spooked by their lead gene therapy’s poor performance on a key measure reflecting potential durability. Today, the top execs at the company are making a new pitch, hoping that they can win over the market with updated evidence that the gene therapy is working for patients with Fabry disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
